Naloxegol
Sponsors
UZ Leuven, AstraZeneca, Kyowa Kirin Pharmaceutical Development Ltd, Massachusetts General Hospital, Michael Camilleri
Conditions
Brain InjuriesCancerConstipationConstipation Drug InducedConstipation, Signs and Symptoms, DigestiveCritical IllnessDrug Induced ConstipationEsophagus Disorder
Phase 1
Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol
CompletedNCT01594619
Start: 2012-05-31End: 2012-08-31Updated: 2014-10-15
Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol
CompletedNCT01623609
Start: 2012-07-31End: 2012-09-30Updated: 2014-10-15
Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients
CompletedNCT02099591
Start: 2014-11-30End: 2021-04-30Updated: 2024-06-17
Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects
CompletedNCT02737059
Start: 2016-07-01End: 2017-05-10Updated: 2017-08-30
Phase 2
Naloxegol in Cancer Opioid-Induced Constipation
TerminatedNCT02745353
Start: 2016-05-31End: 2017-06-22Updated: 2019-12-09
Movantik for Opioid-Related Esophageal Disorders
TerminatedNCT02998606
Start: 2017-01-31End: 2018-10-31Updated: 2018-12-24
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
TerminatedNCT03087708
Start: 2018-03-23End: 2023-04-01Updated: 2025-07-17
Phase 3
The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit
WithdrawnNCT02705378
Start: 2017-05-31End: 2019-12-31Updated: 2021-05-05
Effect of Naloxegol on Postoperative Ileus in Patients Undergoing Cardiac Surgery
CompletedNCT04433390
Start: 2020-10-14End: 2022-03-03Updated: 2022-03-08
The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients
RecruitingNCT05008926
Start: 2022-03-15End: 2026-09-15Target: 370Updated: 2025-11-21
Phase 4
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
TerminatedNCT02839889
Start: 2016-09-30End: 2018-01-11Updated: 2019-03-05
Colonic Motor Patterns in Healthy Volunteers
CompletedNCT05770960
Start: 2018-06-27End: 2019-05-09Updated: 2023-03-16
Double-blind placebo-controlled cross-over MRI study to evaluate the effect of naloxegol and codeine on gastrointestinal motility and volumes
CompletedCTIS2024-512673-28-00
Start: 2024-10-28End: 2025-07-03Target: 15Updated: 2024-09-16
Unknown Phase
Naloxegol Drug Utilization Post Authorisation Safety Study
CompletedNCT02813148
Start: 2015-08-31End: 2020-01-31Updated: 2024-07-23
Naloxegol Health Outcome Post Authorisation Safety Study
TerminatedNCT02813369
Start: 2016-09-30End: 2021-11-30Updated: 2024-07-23
Naloxegol US PMR CV Safety.
NCT02813356
Start: 2016-06-24End: 2023-12-31Target: 8800Updated: 2023-05-15
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
CompletedNCT03638440
Start: 2018-08-16End: 2020-03-05Updated: 2024-06-17
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
RecruitingNCT03720613
Start: 2019-01-04End: 2030-11-01Target: 34532Updated: 2025-02-12
Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol
CompletedNCT04173858
Start: 2017-09-21End: 2019-10-31Updated: 2019-11-22
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
CompletedNCT04294550
Start: 2018-09-01End: 2021-03-31Updated: 2022-02-28